Search research articles
Contact Us
Filters
Showing results (721-730 of 831) with videos related to
Page
of 84
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 5, 2016
Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082)
Wolfgang Wick, Thierry Gorlia, Pierre Bady, et al.
Acta Neuropathologica
|
October 15, 2017
Rare ADAR and RNASEH2B variants and a type I interferon signature in glioma and prostate carcinoma risk and tumorigenesis
Ulrike Beyer, Frank Brand, Helge Martens, et al.
Acta Neuropathologica
|
June 20, 2015
Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities
David E Reuss, Annekathrin Kratz, Felix Sahm, et al.
Neurology
|
July 18, 2023
IV Thrombolysis With or Without Endovascular Treatment for Suspected Ischemic Stroke in Patients With Intracranial Tumors
Katharina Seystahl, Nicolas Martinez-Majander, Alexander Salerno, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 18, 2021
Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma
Paul M J Clement, Linda Dirven, Marica Eoli, et al.
The Lancet. Oncology
|
May 10, 2017
European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas
Michael Weller, Martin van den Bent, Jörg C Tonn, et al.
The Lancet. Oncology
|
January 5, 2024
PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group
Nathalie L Albert, Norbert Galldiks, Benjamin M Ellingson, et al.
Neuro-Oncology
|
April 4, 2017
Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG
Deborah T Blumenthal, Thierry Gorlia, Mark R Gilbert, et al.
Neuro-Oncology Practice
|
July 19, 2021
Systematic review on the use of patient-reported outcome measures in brain tumor studies: part of the Response Assessment in Neuro-Oncology Patient-Reported Outcome (RANO-PRO) initiative
Linda Dirven, Maartje E Vos, Tobias Walbert, et al.
Acta Neuropathologica
|
September 30, 2022
The proteomic landscape of glioblastoma recurrence reveals novel and targetable immunoregulatory drivers
Nazanin Tatari, Shahbaz Khan, Julie Livingstone, et al.
Page
of 84
Search research articles
Search
Showing results (721-730 of 831) with videos related to
Sort By:
Page
of 84
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 5, 2016
Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082)
Wolfgang Wick, Thierry Gorlia, Pierre Bady, et al.
Acta Neuropathologica
|
October 15, 2017
Rare ADAR and RNASEH2B variants and a type I interferon signature in glioma and prostate carcinoma risk and tumorigenesis
Ulrike Beyer, Frank Brand, Helge Martens, et al.
Acta Neuropathologica
|
June 20, 2015
Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities
David E Reuss, Annekathrin Kratz, Felix Sahm, et al.
Neurology
|
July 18, 2023
IV Thrombolysis With or Without Endovascular Treatment for Suspected Ischemic Stroke in Patients With Intracranial Tumors
Katharina Seystahl, Nicolas Martinez-Majander, Alexander Salerno, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 18, 2021
Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma
Paul M J Clement, Linda Dirven, Marica Eoli, et al.
The Lancet. Oncology
|
May 10, 2017
European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas
Michael Weller, Martin van den Bent, Jörg C Tonn, et al.
The Lancet. Oncology
|
January 5, 2024
PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group
Nathalie L Albert, Norbert Galldiks, Benjamin M Ellingson, et al.
Neuro-Oncology
|
April 4, 2017
Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG
Deborah T Blumenthal, Thierry Gorlia, Mark R Gilbert, et al.
Neuro-Oncology Practice
|
July 19, 2021
Systematic review on the use of patient-reported outcome measures in brain tumor studies: part of the Response Assessment in Neuro-Oncology Patient-Reported Outcome (RANO-PRO) initiative
Linda Dirven, Maartje E Vos, Tobias Walbert, et al.
Acta Neuropathologica
|
September 30, 2022
The proteomic landscape of glioblastoma recurrence reveals novel and targetable immunoregulatory drivers
Nazanin Tatari, Shahbaz Khan, Julie Livingstone, et al.
Page
of 84